PRCT vs TYRA: Which Stock Is the Better Buy?
PROCEPT BioRobotics Corporation and Tyra Biosciences, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — PRCT vs TYRA, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| PROCEPT BioRobotics Corporation (PRCT) | Tyra Biosciences, Inc. (TYRA) | |
|---|---|---|
| Market cap | $1.5B | $1.6B |
| Revenue (latest FY) | $308.05M | $0 |
| Net income (latest FY) | $-95.57M | $-119.95M |
| Revenue growth (5y CAGR) | 109.0% | — |
| Net margin | -31.0% | — |
| Return on equity | -26.1% | -46.3% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full PRCT vs TYRA breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open PRCT's full financials → Open TYRA's full financials →More comparisons
Frequently asked questions
Which is bigger, PRCT or TYRA?
Tyra Biosciences, Inc. is larger by market capitalization — $1.6B versus $1.5B.
Which grows faster, PRCT or TYRA?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.
Keep exploring
PRCT fundamentals → · TYRA fundamentals → · All 1,500+ companies → · Free screener →